Europe/Asia USA
Bachem AG Bachem Americas, Inc.
Hauptstrasse 144 3132 Kashiwa Street
4416 Bubendorf - Switzerland Torrance, CA 90505 - USA
Tel +41 61 935 2323 Tel +1 888 422 2436
Fax +41 61 935 2325 +1 888 4BACHEM
E-mail sales.ch@bachem.com +1 310 539 4171
  Fax +1 310 539 9428
  E-mail sales.us@bachem.com

PEPTIDE TRENDS JULY 2015

Alzheimer`s Assoziation

Meet us at Alzheimer`s AssoCiation International Conference, Washington, D.C., United States

 

Every year this Association brings together investigators and practitioners for larger discussions that advance the field. This year program will explore a range of Alzheimer’s and dementia topics. Join us at AAIC® this year for more than 85 sessions and 1,800 poster and oral presentations featuring the latest dementia research from around the globe.

 

We offer more than 160 Alzheimer’s research catalog proteomic products including over 20 new Amyloid-beta catalog peptides and we will welcome you at booth #330. To schedule a personal meeting please send an email.

 

 

Alzheimer`s Disease - A review

 

Alzheimer's disease (AD) is the most common type of dementia and accounts for an estimated 60–80% of the reported cases. It is estimated that over 35 million people worldwide have dementia, and this figure is expected to triple by 2050 with a trend of an aging global population. Dementia is characterized by a loss or decline in memory and other cognitive abilities. AD is an irreversible, progressive neurodegenerative disorder. A worldwide struggle is under way to find new treatments and therapies to prevent, cure or even slow the progress of Alzheimer's disease. The presence of senile plaques, neurofibrillary tangles, neutrophil threads, Beta-Amyloid (Aβ) peptide deposits, and selective loss of neurons are some of the distinctive characteristics of the disease.

The most common feature of the disease is amyloid plaque deposits. Initially Aβ starts as a solitary molecule and tends to come together in the form of clusters which are still soluble and are capable of free travel in the brain, and finally clusters form plaques that are hallmark of AD. Studies show that Aβ has strong binding affinity to the receptors on nerve cells triggering an intracellular process that erodes their synapses with other nerve cells. Aβ are chemically "sticky" and gradually build up into plaques. Aβ peptides are proteolytically cleaved from the membrane bound amyloid precursor protein (APP) which are major constituents of these deposits. The peptides result from the APP, which are being cut by certain enzymes to yield Aβ. Aβ molecules can aggregate to form flexible soluble oligomers which may exist in several forms. It is now believed that certain misfolded oligomers act as seeds, can induce other Aβ molecules to also take the misfolded oligomeric form, leading to a chain reaction. The seeds or the resulting amyloid plaques are toxic to nerve cells. Plaques and tangles tend to spread through the cortex in a predictable pattern as AD progresses. The familial AD genetic evidence shows relation between metabolism of Aβ and AD disease. This progressive brain disorder that damages and eventually destroys the brain cells, leading to dementia and decline in other brain functions, eventually leading to the death of brain cells.

Therefore Alzheimer's is fatal, and unfortunately so far there is no cure. Alzheimer's brain abnormalities, including but not limited to:

  • Plaques (microscopic clumps of a protein fragment called beta-amyloid (Aβ). These sticky brain plaques are known to consist mainly of Aβ and are known to build up in brain many years before the actual Alzheimer's symptoms start.
  • Tangles, twisted microscopic strands of the protein tau. Tangles destroy a vital cell transport system made of proteins.
  • Loss of connections among brain cells responsible for memory, learning and communications. These connections, or synapses, transmit information from cell to cell.
  • Inflammation, triggered by body's immune system
  • Eventual death of brain cells and severe tissue shrinkage leading to the brain lesions.

Aβ plays crucial role in AD, and its high concentration (Nano to micro molar) in the brain can cause neuronal death. Pica molar concentration of Aβ slow down the memory and learning process. The Aβ peptide levels in the brain are dynamically and directly influenced by synaptic activity. Low amounts of Aβ, could work as antioxidants, due to its ability to capture redox metals, such as Cu, Fe and Zn, and thus, preventing their participation in redox cycling with other ligands. Aβ peptide has neurotrophic properties and it is hence responsible for the growth and survival of neurons, in the modulation of synaptic function and defense against oxidative stress. The physiological concentrations of Aβ favor the learning and memory processes.

 

 

Image courtesy: M. del C. Cárdenas-Aguayo, M. del C. Silva-Lucero, M. Cortes-Ortiz, B. Jiménez-Ramos, L. Gómez-Virgilio, G. Ramírez-Rodríguez, E. Vera- Arroyo, R. Fiorentino-Pérez, U. García, J. Luna-Muñoz and M.A. Meraz-Ríos DOI: 10.5772/57398; click here for details. 

 

 

Role of Beta Amyloid in the early detection of Alzheimer`s disease

 

The role of Aβ40 and Aβ42 peptides in the early pathogenesis of the AD has been frequently emphasized in the literature. These two peptides have received tremendous interest in modern AD research. Aβ40 and Aβ42 are major products of the proteolytic cleavage of multi domain integral membrane type-1 protein, APP which play important role in cell adhesion, neuronal mobility and transcriptional regulation. Among the two peptides, Aβ42 is known to be more prone to aggregation than Aβ40, even though they only differ in two (IA) amino acid residues at the C-terminal end. The metabolism of APP involves proteases/secretase processing to yield intra and extra cellular fragments that play important role in synaptic transmission and neuronal plasticity. Amyloidogenic pathway is responsible for beta amyloids peptides through the action of beta and gamma secretases.

 

Aβ insoluble aggregates in the brain are hallmark of AD, these peptides do exists as soluble aggregates as well. In vitro experiments have obtained fibrillar and different non-fibrillar aggregates. Hexafluoroisopropanol (HFIP) has been used as solvent to dissolve Aβ and other amyloidogenic peptides. HFIP has been used to obtain in vitro a highly ordered fibrillary and variety of non-fibrillar aggregates of beta amyloids. Studies at CSIR/CCMB-India shows the dissolution of Aβ40 and Aβ42 in HFIP and the drying results in highly ordered aggregates. The observed alpha helical confirmation is not stable for prolonged periods. Once the Aβ40, and Aβ42 are incubated in HFIP for longer period of time and eventually dried led to structural transition from alpha helical to beta helical conformation. Then the peptides tend to form short fibrous aggregates that further assemble into highly ordered ring like structures leading to enhancement of thioflavin T fluorescence. The researchers at CSIR-CCMB conclude that dissolution of Aβ40 and Aβ42 or other amyloidogenic fragments in HFIP results formation of structures that are like annular amyloid. 

 

         

 

Bachem offers H-7442 and H-7438 which are Beta Amyloid (1-42) and (1-40) peptides treated with HFIP.

Till date it has only been possible to detect AD in late stage when there has already been significant damage to brain. Aβ can be detected in cerebrospinal fluid through a lumbar region puncture and PET (Positron emission tomography) scans. Both being expensive and not easily available everywhere.

Beta amyloid build-up in the eyes of patients in early years has become a biomarker for this disease. The peptide build-up begins 15-20 years before the Alzheimer's symptoms appear. Studies were conducted and concluded to find significant correlation of the levels of Aβ build-up in eyes and the Aβ build-up in the brain. An abstract prepared by the scientists for AAIC 2014 gives the results for 40 participants out of 200 totals in the study.

 

References:

www.ncbi.nlm.nih.gov/pmc/articles/PMC1978067/

www.alz.org/braintour/plaques.asp

med.stanford.edu/news/all-news/2013/09/scientists-reveal-how-beta-amyloid-may-cause-alzheimers.html

www.jbc.org/content/278/13/11612

www.ncbi.nlm.nih.gov/pubmed/22252985

   

 

 

20 % Summer Special*: Alzheimer`s disease products 

 

From now on till September 30, 2015, we are offering a 20% saving on more than 160 Alzheimer`s disease related products ordered online.

Simply use the following discount code at checkout while you place your online order: AD20

 

 

 

 

New Beta-Amyloid Peptides  

 

H-7442

Amyloid β-Protein (1-42) (HFIP-treated)

New Pack Size

H-7438

Amyloid β-Protein (1-40) (HFIP-treated)

New Pack Size

H-1194

Amyloid β-Protein (1-40) TFA salt

New Pack Size

H-5568

Amyloid β-Protein (1-40) HCl salt

New Pack Size

H-7456

Biotinyl-εAhx-Amyloid β-Protein (1-40)

New Pack Size

H-7418

(Cys²)-Amyloid β-Protein (1-40) (Dimer)

New Pack Size

H-7446

5-FAM-Amyloid β-Protein (1-40)

New Pack Size

H-7476

(Met(O)³)-Amyloid β-Protein (1-40)

H-7452

5-TAMRA-Amyloid β-Protein (1-40)

New Pack Size

H-1368

Amyloid β-Protein (1-42)

New Pack Size

H-5642

Biotinyl-Amyloid β-Protein (1-42)

New Pack Size

H-7406

Amyloid β-Protein (1-42) (scrambled)

H-7408

Amyloid β-Protein (1-40) (scrambled)

H-7402

(Cys²)-Amyloid β-Protein (1-40)

H-7412

(Gln²²,Asn²³)-Amyloid β-Protein (1-40)

H-7474

(Des-Glu²²)-Amyloid β-Protein (1-40)

H-7444

5-FAM-Amyloid β-Protein (1-42)

New Pack Size

H-7448

5-TAMRA-Amyloid β-Protein (1-42)

New Pack Size

H-7414

(Val³)-Amyloid β-Protein (1-40)

H-7462

Amyloid β-Protein (1-37)

H-7458

Amyloid β-Protein (1-39)

H-7422

(Pyr³)-Amyloid β-Protein (3-40)

H-7532

Amyloid β-Protein (17-40)     

 

 

* 20% discount for online orders only. Cannot be combined with other discounts. Bulk orders not included. Valid until September 30, 2015. Some restrictions may apply.

The Interview: Violeta Jordan, Global Director of Product Management, Bachem

 

PT: Violeta, tell us what you do at Bachem?

Violeta: I am the Global Director of Product Management and I report to the Bachem headquarter located in Bubendorf, Switzerland, but I live in San Francisco. Product Management is part of the Global Marketing Team and we as a team and in the same time as a peptide partner work on many different research catalog and custom marketing projects including existing and future collaborations, new peptide technologies, new products, marketing of our products, and attending scientific symposiums.

 

PT: How long have you been with Bachem and what did you do before?

Violeta: I am at Bachem since 2013. I started my training as a bench scientist in Zeneca, work in Sales for Semiconductor Industry, Manage Sales Team for Wireless Technology and for the last 10 years before joining Bachem I was a Global Director of Sales and Marketing Team for a Peptide company located in California.

 

PT: What is your academic background/degrees or training?

Violeta: I have a BS degree in Chemistry and Agriculture from the University of Macedonia in Skopje and MBA from the Golden Gate University in San Francisco, California.

 

PT: Last but not least, what do you like to do outside of Bachem?

Violeta: I enjoy swimming, traveling, symphony, ballet and walking the hidden staircases of San Francisco.

 

PT: Thank you very much Violeta.

 

Literature citings 

 

Bachem peptides and biochemicals are widely cited in research publications. Congratulations to all our customers with recent publications! 

 

Lowe, J. D., Sanderson, H. S., Cooke, A. E., Ostovar, M., Tsisanova, E., Withey, S. L., Chavkin, C., Husbands, S. M., Kelly, E., Henderson, G. and Bailey, C. P.

Role of G Protein-Coupled Receptor Kinases 2 and 3 in mu-Opioid Receptor Desensitization and Internalization.

Mol. Pharmacol. 88, 347-356 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=26013542

 

Ulrich, D.

Amyloid-beta Impairs Synaptic Inhibition via GABAA Receptor Endocytosis.

J. Neurosci. 35, 9205-9210 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=26085642

 

Mietlicki-Baase, E. G., Olivos, D. R., Jeffrey, B. A. and Hayes, M. R.

Cooperative interaction between leptin and amylin signaling in the ventral tegmental area for the control of food intake.

Am J Physiol Endocrinol Metab 308, E1116-1122 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=25898952

 

Dai, C., Basilico, P., Cremona, T. P., Collins, P., Moser, B., Benarafa, C. and Wolf, M.

CXCL14 Displays Antimicrobial Activity against Respiratory Tract Bacteria and Contributes to Clearance of Streptococcus pneumoniae Pulmonary Infection.

J. Immunol. 194, 5980-5989 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=25964486

 

Park, M. H., Jin, H. K., Min, W. K., Lee, W. W., Lee, J. E., Akiyama, H., Herzog, H., Enikolopov, G. N., Schuchman, E. H. and Bae, J. S.

Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

EMBO J. 34, 1648-1660 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=25916827

 

Park, H. J., Ran, Y., Jung, J. I., Holmes, O., Price, A. R., Smithson, L., Ceballos-Diaz, C., Han, C., Wolfe, M. S., Daaka, Y., Ryabinin, A. E., Kim, S. H., Hauger, R. L., Golde, T. E. and Felsenstein, K. M.

The stress response neuropeptide CRF increases amyloid-beta production by regulating gamma-secretase activity.

EMBO J. 34, 1674-1686 (2015)

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=25964433

 

 

Bachem football

Peptide Puzzler

How many Alzheimer`s Disease related products are available @ shop.bachem.com ?

A.) less than 87

B.) more than 160

C.) more than 187

 

Rules

 

Submit the correct answer to puzzle@bachem.com by 12:01 am Los Angeles time on Friday, June 19, 2015 for your chance to win a Bachem football. 

 

 

 

PEPTIDE Highlights

 

News about peptides in basic research and pharmaceutical development:

 

Potential obesity treatment targets the 2 sides of appetite: Hunger and feeling full- EurekAlert!

 

Educating the immune system to prevent allergies-ScienceDaily

 

How to reset a diseased cell-UC San Diego Health System

 

University of Oslo researchers confirm new mechanism for Alzheimer's disease-Medical Xpress